Neurizon locks in global trademark protection across key pharma markets

The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection

HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs

Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells

AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing

The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange

Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments

Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025

Kindeva appoints David Stevens as new CEO

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors

IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis

The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability